stockrowInogen, Inc
INGN Healthcare Medical Devices
Inogen, Inc’s revenue for fiscal 2025 (year ended December 2025) was $348.7 million, up 3.86% from fiscal 2024.
- Revenue
- +3.04%
- EPS
- +6.67%
- Free cash flow
- −51.2%
Quarter to June 2026, against a year earlier
Follow INGN
Alert me
Inogen, Inc (INGN) EV/Sales
As of 5 November 2026, Inogen, Inc (INGN) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −0.1× (September 2023) to 18.7× (September 2018); the current reading is higher than 19% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.2× | (43.90%) |
| FY2024 | 0.3× | 2,928.57% |
| FY2023 | 0.0× | (98.62%) |
| FY2022 | 0.7× | (51.17%) |
| FY2021 | 1.5× | (40.41%) |
| FY2020 | 2.4× | (31.27%) |
| FY2019 | 3.5× | (47.16%) |
| FY2018 | 6.7× | (27.02%) |
| FY2017 | 9.2× | 55.04% |
| FY2016 | 5.9× | 35.50% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.2× | 16.80% |
| Mar 2026 | 0.2× | (1.68%) |
| Dec 2025 | 0.2× | (40.34%) |
| Sep 2025 | 0.3× | 45.21% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. compare | −2.5× |
| RXST RxSight, Inc. compare | −0.4× |
| INGN Inogen, Inc | 0.2× |
| QTRX Quanterix Corporation compare | 0.3× |
| MXCT MaxCyte, Inc. compare | 1.3× |
| STIM Neuronetics, Inc. compare | 1.5× |
| ELMD Electromed, Inc. compare | 2.7× |
| TLSI TriSalus Life Sciences, Inc. compare | 4.3× |
| PROF Profound Medical compare | 9.6× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)